Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Entropy NeurodynamicsASX:ENP EV-to-OCF is -9.62 as of Aug. 01, 2026. The stock has 5 warning signs investors should review. Among 1,410 Biotechnology companies, Entropy Neurodynamics ranks better than 70.64% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Entropy Neurodynamics's Enterprise Value is A$51.35 Mil.
Entropy Neurodynamics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.34 Mil. Therefore, Entropy Neurodynamics's EV-to-OCF for today is -9.62.
The historical rank and industry rank for Entropy Neurodynamics's EV-to-OCF or its related term are showing as below:
ASX:ENP'
s EV-to-OCF Range Over the Past 10 Years
Min: -10.24 Med: -0.63 Max: -0.04
Current: -10.24
During the past 7 years, the highest EV-to-OCF of Entropy Neurodynamics was -0.04. The lowest was -10.24. And the median was -0.63.
ASX:ENP's EV-to-OCF is ranked better than 70.64% of 1410
companies
in the Biotechnology industry
Industry Median: -3.345
vs ASX:ENP: -10.24
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Entropy Neurodynamics's PE Ratio (TTM) for today is calculated as:
Entropy Neurodynamics's share price for today is A$0.035.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Entropy Neurodynamics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Entropy Neurodynamics's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Entropy Neurodynamics EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Entropy Neurodynamics's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Entropy Neurodynamics's EV-to-OCF falls into.
Entropy Neurodynamics's current Enterprise Value is A$51.35 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Entropy Neurodynamics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was A$-5.34 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Entropy Neurodynamics (ASX:ENP) has a EV-to-OCF of -9.62 as of Aug. 01, 2026. According to the industry distribution chart, Entropy Neurodynamics ranks #414 out of 1410 companies in the Biotechnology industry, placing it in the top 29.4%.
Is Entropy Neurodynamics' EV-to-OCF too high?
Entropy Neurodynamics' current EV-to-OCF is -9.62. Based on the distribution chart, Entropy Neurodynamics ranks #414 out of 1410 companies in the Biotechnology industry, which is above the industry midpoint.
How does Entropy Neurodynamics' EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Entropy Neurodynamics ranks #414 out of 1410 companies for EV-to-OCF. This puts Entropy Neurodynamics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Entropy Neurodynamics's current EV-to-OCF is -9.62. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entropy Neurodynamics stock overvalued right now?
Based on GuruFocus' analysis, Entropy Neurodynamics (ASX:ENP) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.04 — trading 16.7% above its estimated fair value. The current EV-to-OCF is -9.62. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Entropy Neurodynamics (ASX:ENP), the current EV-to-OCF is -9.62 as of Aug. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Entropy Neurodynamics Ltd is a clinical-stage biotechnology company focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company's lead program is TRP-8803. TRP-8803 is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin including: significantly reducing the time to onset of the psychedelic state, controlling the depth and duration of the psychedelic experience, and reducing the overall duration of the intervention to a commercially feasible timeframe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ENP has been successfully added to your 
